DelveInsight’s, “Merkel Cell Carcinoma Pipeline Insight, 2023,” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in the Merkel Cell Carcinoma pipeline landscape. It covers the Merkel Cell Carcinoma pipeline drug profiles, including Merkel Cell Carcinoma clinical trials and nonclinical stage products. It also covers the Merkel Cell Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Merkel Cell Carcinoma Emerging drugs, the Merkel Cell Carcinoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Merkel Cell Carcinoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Merkel Cell Carcinoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Merkel Cell Carcinoma clinical trials studies, Merkel Cell Carcinoma NDA approvals (if any), and product development activities comprising the technology, Merkel Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Merkel Cell Carcinoma Pipeline Report

 

• DelveInsight’s Merkel Cell Carcinoma Pipeline analysis depicts a robust space with 14+ active players working to develop 14+ pipeline treatment therapies.

 

• The leading Merkel Cell Carcinoma Companies includes ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos therapeutics, Incyte corporation, Amgen, BioInvent International AB, SOTIO Biotech, Xencor, Exicure, Checkmate Pharmaceuticals, Takeda, Genocea Biosciences, NeoImmuneTech, Sensei Biotherapeutics, and others.

 

• Promising Merkel Cell Carcinoma Pipeline Therapies includes XmAb18087, XmAb18087 ± Pembrolizumab, GLA-SE, Pembrolizumab (MK-3475), Retifanlimab, Pasireotide sub-cutaneous formulation Tavokinogene Telseplasmid (tavo), Avelumab, MLN0128, Nivolumab, and others.

 

• The Merkel Cell Carcinoma companies and academics are working to assess challenges and seek opportunities that could influence Merkel Cell Carcinoma R&D. The Merkel Cell Carcinoma pipeline therapies under development are focused on novel approaches to treat/improve Merkel Cell Carcinoma.

 

Request a sample and discover the recent breakthroughs happening in the Merkel Cell Carcinoma Pipeline landscape @ Merkel Cell Carcinoma Pipeline Outlook Report

 

Merkel Cell Carcinoma Overview

Merkel cell carcinoma (MCC) is a rare, aggressive form of skin cancer with a high risk for returning (recurring) and spreading (metastasizing), often within two to three years after initial diagnosis. Merkel cells are located deep in the top layer of skin. Merkel cells are connected to nerves, signaling touch sensation as “touch receptors.” MCC tumors often, but not always, appear on sun-exposed areas of the body. The tumors are not nearly as distinctive as other skin cancers and can appear as a pearly pimple-like lump, sometimes skin-colored, red, purple or bluish-red, though they are rarely tender to the touch. Treatments for Merkel cell carcinoma can include: surgery, Radiation therapy, immunotherapy, and chemotherapy.

 

Recent Developmental Activities in the Merkel Cell Carcinoma Treatment Landscape

 

• The U.S. Food and Drug Administration (FDA) has granted two Fast Track designations to cavrotolimod (AST-008). Exicure initiated the Phase II stage of the clinical trial with dose-expansion cohorts of intratumoral cavrotolimod in combination with approved checkpoint inhibitors to treat two cohorts of patients with locally advanced or metastatic MCC or CSCC.

 

• 4SC has also signed a drug supply agreement with Merck KGaA for avelumab (anti-PD-L1 antibody) to conduct a Phase II clinical trial of domatinostat in combination with avelumab in advanced-stage Merkel cell carcinoma (MCC) patients progressing on previous anti-PD-(L)1 monotherapy (MERKLIN 2).

 

For further information, refer to the detailed Merkel Cell Carcinoma Drugs Launch, Merkel Cell Carcinoma Developmental Activities, and Merkel Cell Carcinoma News, click here for Merkel Cell Carcinoma Ongoing Clinical Trial Analysis

 

Merkel Cell Carcinoma Pipeline Therapeutics Assessment

There are approx. 14+ key companies which are developing the therapies for Merkel Cell Carcinoma. The companies which have their Merkel Cell Carcinoma drug candidates in the most advanced stage, i.e. Phase II include, 4SC.

 

Merkel Cell Carcinoma Pipeline Segmentation

 

Phases

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Route of Administration

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

 

Molecule Type

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

 

Find out more about the Merkel Cell Carcinoma Pipeline Segmentation, Therapeutics Assessment, and Merkel Cell Carcinoma Emerging Drugs @ Merkel Cell Carcinoma Treatment Landscape

 

Scope of the Merkel Cell Carcinoma Pipeline Report

 

• Coverage- Global

 

• Merkel Cell Carcinoma Companies- ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos therapeutics, Incyte corporation, Amgen, BioInvent International AB, SOTIO Biotech, Xencor, Exicure, Checkmate Pharmaceuticals, Takeda, Genocea Biosciences, NeoImmuneTech, Sensei Biotherapeutics, and others.

 

• Merkel Cell Carcinoma Pipeline Therapies includes XmAb18087, XmAb18087 ± Pembrolizumab, GLA-SE, Pembrolizumab (MK-3475), Retifanlimab, Pasireotide sub-cutaneous formulation Tavokinogene Telseplasmid (tavo), Avelumab, MLN0128, Nivolumab, and others.

 

• Merkel Cell Carcinoma Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action

 

Dive deep into rich insights for drugs for Merkel Cell Carcinoma Pipeline Companies and Therapies, click here @ Merkel Cell Carcinoma Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Merkel Cell Carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Mid Stage Products (Phase II)
7. Domatinostat: 4SC
8. Drug profiles in the detailed report…..
9. Early Stage Products (Phase I/II)
10. XmAb18087: Xencor
11. Drug profiles in the detailed report…..
12. Preclinical stage products
13. SNS-401-NG: Sensei Biotherapeutics
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Merkel Cell Carcinoma Key Companies
17. Merkel Cell Carcinoma Key Products
18. Merkel Cell Carcinoma- Unmet Needs
19. Merkel Cell Carcinoma- Market Drivers and Barriers
20. Merkel Cell Carcinoma- Future Perspectives and Conclusion
21. Merkel Cell Carcinoma Analyst Views
22. Merkel Cell Carcinoma Key Companies
23. Appendix

 

Got Queries? Find out the related information on Merkel Cell Carcinoma Mergers and acquisitions, Merkel Cell Carcinoma Licensing Activities @ Merkel Cell Carcinoma Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/